

## Complete Summary

---

### GUIDELINE TITLE

Multiple myeloma (MM).

### BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Multiple myeloma (MM). In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2005 May 1 [Various].

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Vilpo J. Multiple myeloma (MM). In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2004 Jun 14 [various].

## COMPLETE SUMMARY CONTENT

SCOPE  
 METHODOLOGY - including Rating Scheme and Cost Analysis  
 RECOMMENDATIONS  
 EVIDENCE SUPPORTING THE RECOMMENDATIONS  
 BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
 IMPLEMENTATION OF THE GUIDELINE  
 INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
 CATEGORIES  
 IDENTIFYING INFORMATION AND AVAILABILITY  
 DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Multiple myeloma (MM)

### GUIDELINE CATEGORY

Diagnosis  
 Evaluation  
 Management  
 Treatment

### CLINICAL SPECIALTY

Family Practice  
Internal Medicine  
Oncology

## INTENDED USERS

Health Care Providers  
Physicians

## GUIDELINE OBJECTIVE(S)

Evidence-Based Medicine Guidelines collect, summarize, and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.

## TARGET POPULATION

- Patients with multiple myeloma (MM)
- Patients requiring evaluation for possible multiple myeloma

## INTERVENTIONS AND PRACTICES CONSIDERED

### Evaluation/Diagnosis

1. Use of World Health Organization (WHO) Diagnostic Criteria
2. Differential diagnosis
3. Laboratory tests: blood picture, serum calcium, potassium, sodium and creatinine, and erythrocyte sedimentation rate (ESR); bone marrow examination; serum and urine protein electrophoresis
4. Additional investigations, as indicated:
  - X-ray (skull, thorax/ribs, backbone, scapulae, pelvis and long bones of the extremities)
  - Serum/plasma total protein, albumin, potassium, sodium, calcium, ionised calcium, creatinine, urate and immunoglobulins (IgG, IgA, IgM)
  - Identification of M component heavy and light chains by immunofixation or by other means
  - Magnetic resonance imaging as indicated

### Treatment/Management

1. Early treatment of complications
2. Follow-up, including assessment of:
  - The amount of M component (serum and/or urine)
  - Degree of bone marrow infiltrates
  - General condition and symptoms, infections and (bone) pains
  - Osteolytic lesions (x-ray)
  - Renal function, hypercalcaemia and blood picture
3. Chemotherapy
  - Vincristine, adriamycin, and dexamethasone (VAD) or similar combinations
  - MP therapy (a combination of melphalan and prednisolone)

- Refractory cases
  - VAD (vincristine, adriamycin and dexamethasone)
  - MOCCA (vincristine, cyclophosphamide, lomustine, melphalan and methylprednisolone), high-dose melphalan or other cytostatics
  - Thalidomide
  - Dexamethasone
  - Proteasome inhibitors
- Interferon
- 4. Supportive therapy
  - Maintenance of fluid and electrolyte balance
  - Treatment of hypercalcaemia
  - Treatment of infections
  - Maintenance of mobility
  - Treatment of anaemia and thrombocytopenia, if necessary
- 5. Stem cell transplantation (autologous or allogeneic) as indicated

#### MAJOR OUTCOMES CONSIDERED

- Survival (lifetime and progression-free)
- Mortality
- Adverse effect associated with treatment

### METHODOLOGY

#### METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)  
 Hand-searches of Published Literature (Secondary Sources)  
 Searches of Electronic Databases

#### DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The evidence reviewed was collected from the Cochrane database of systematic reviews and the Database of Abstracts of Reviews of Effectiveness (DARE). In addition, the Cochrane Library and medical journals were searched specifically for original publications.

#### NUMBER OF SOURCE DOCUMENTS

Not stated

#### METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

#### RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Levels of Evidence

- A. Strong research-based evidence. Multiple relevant, high-quality scientific studies with homogeneous results.
- B. Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.
- C. Limited research-based evidence. At least one adequate scientific study.
- D. No research-based evidence. Expert panel evaluation of other information.

#### METHODS USED TO ANALYZE THE EVIDENCE

Review of Published Meta-Analyses  
Systematic Review

#### DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

#### METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

#### RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

#### COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

#### METHOD OF GUIDELINE VALIDATION

Peer Review

#### DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated

### RECOMMENDATIONS

#### MAJOR RECOMMENDATIONS

The levels of evidence [A-D] supporting the recommendations are defined at the end of the "Major Recommendations" field.

##### Aim

To recognize symptoms that require early intervention

##### Pathology

- Multiple myeloma (MM) is a clonal bone marrow proliferation of mature B cells (plasma cells) characterized by a monoclonal immunoglobulin fraction (M component) in the serum or sometimes only in urine protein electrophoresis.
- Benign disease forms (monoclonal gammopathy with unknown significance [MGUS] and benign paraproteinaemia) are about 100 times more common than myeloma.

### Epidemiology

- Approximately 3 to 4 new cases/100,000/year
- Diagnosis is usually made at the age of 50 to 70 years, rarely before the age of 40 years.
- No sex differences

### Aetiology

- In individual patients aetiology remains unknown.
- Ionizing radiation slightly increases the risk.

### Diagnosis

- The main diagnostic difficulty is to make a distinction between early cases of MM and "benign" paraproteinaemias, especially MGUS.

### Criteria for Diagnosis of Multiple Myeloma (World Health Organization [WHO] Classification)

- A. The diagnosis of multiple myeloma requires one main criterion and at least one additional criterion OR three additional criteria, which include C1 and C2. In addition, the disease has to be symptomatic and progressive.
- B. Main criteria
  1. Bone marrow plasmacytosis (>30%)
  2. Plasmacytoma in biopsy
  3. M component
    - Serum/plasma: Immunoglobulin G (IgG) >35 g/L, IgA >20 g/L
    - Urine: >1 g/24 h
- C. Additional criteria
  1. Bone marrow plasmacytosis (10–30%)
  2. M component (smaller than in point B)
  3. Osteolytic lesions
  4. Decrease of polyclonal immunoglobulins in serum
    - IgG <6 g/L
    - IgA <1 g/L
    - IgM <0.5 g/L

### Differential Diagnostics

- MGUS (plasma cells in bone marrow <10%; IgG <35 g/L or IgA <20 g/L, no osteolytic foci, no symptoms). The WHO classification 2001 also includes the traditional "benign" paraproteinaemia in this group.

- Waldenström's macroglobulinaemia (See Finnish Medical Society Duodecim guideline "Waldenström's macroglobulinaemia [WM]")
- Lymphomas with an M component in some cases
- Other rare diseases where there is an M component

### Clinical Picture

- Often:
  - Osteolytic lesions and bone pains
  - Mild anaemia, hypercalcaemia, hyperuricaemia
  - Renal insufficiency
- Rarely:
  - Hyperviscosity syndrome (IgA myeloma)

### Typical Laboratory Findings

- Increased erythrocyte sedimentation rate (ESR) (not in light-chain myeloma)
- M component in serum and/or urine
- Decreased haemoglobin level, often also leuco- and thrombocytopenia
- Malignant plasma cell infiltrates in the bone marrow
- Osteolytic lesion in bone x-ray
- Often increased serum urate and calcium but diminished albumin concentration

### Basic Examinations

- Blood picture, serum calcium, potassium, sodium and creatinine, and ESR
- Bone marrow examination
- Serum and urine protein electrophoresis (M component can be found exclusively in urine in only 10 to 20% of MM patients)

### Additional Investigations when MM is Likely

- X-ray (skull, thorax/ribs, vertebrae, scapulae, pelvis, and long bones of the extremities)
- Serum/plasma total protein, albumin, potassium, sodium, calcium, ionised calcium, creatinine, urate, and immunoglobulins (IgG, IgA, IgM)
- Identification of M component heavy and light chains by immunofixation or by other means
- Magnetic resonance imaging is more sensitive than radiography, but is seldom indicated in basic diagnosis.

### Complications Requiring Attention Preferably Within 24 Hours (Particularly in New Patients)

- Sepsis or pneumonia (intravenous broad-spectrum antibiotics)
- Renal insufficiency (dialysis or haemofiltration)
- Hyperviscosity (plasmapheresis)
- Hypercalcaemia (fluid replacement, bisphosphonates, steroids)
- Spinal cord compression (surgical decompression, radiotherapy)
- Pathological fractures (pain medication, stabilization)

- Vertebral compression (orthopaedic treatment)

### Disease Progression and Prognosis

- With traditional therapies, median life expectancy at diagnosis is about 3.5 to 4 years and somewhat longer with more intensive treatments. Marked individual variation exists.
- Myeloma cells become gradually resistant to chemotherapy.
- Myeloma cell infiltrates occupy the bone marrow causing anaemia, thrombocytopenia, and leucopenia.
- Infections, haemorrhages and renal insufficiency are frequent complications.

### Follow-up and Treatment

- If the patient is symptomless, no chemotherapy is usually given, as it does not improve the patient's wellbeing or prolong life.
- Symptomatic patients are treated actively.

In Follow-up, Attention is Paid to:

- The amount of M component (serum and/or urine)
- The blood picture (reflects the degree of bone marrow infiltrates)
- General condition and symptoms, infections and (bone) pains
- Osteolytic lesions (x-ray)
- Renal function and hypercalcaemia

### Chemotherapy

- According to instructions given by a haematologist or a specialist in internal medicine who is familiar with the treatment of haematological diseases: the aim is intensive therapy and two successive autologous stem cell transplantations (patients under 70 years).
- VAD (vincristine, adriamycin, and dexamethasone) or similar combinations when stem cell transplantation is considered or a rapid response is needed.
- MP therapy (a combination of melphalan and prednisolone) especially for patients over 70 years of age and also for younger patients if stem cell transplantation is not considered
- Refractory cases
  - Vincristine, adriamycin, and dexamethasone (VAD)
  - Vincristine, cyclophosphamide, lomustine, melphalan, and methylprednisolone (MOCCA), high-dose melphalan, or other cytostatics
  - Thalidomide
  - Dexamethasone
  - Proteasome inhibitors
- Interferon may be tried (Trippoli et al., 1997; Database of Abstracts of Reviews of Effectiveness [DARE]-971500, 1999) [B] especially for maintaining an otherwise reached good response.

Supportive Therapy Includes:

- Maintenance of fluid and electrolyte balance (to prevent renal failure)
- Treatment of hypercalcaemia
- Treatment of infections
- Maintenance of mobility in order to prevent osteoporosis and pathological fractures
- If necessary, treatment of anaemia and thrombocytopenia

#### Stem Cell Transplantation

- Autologous stem cell transplantation is used increasingly and is often the first-line treatment for patients over 70 years of age (Johnson et al., 1998; DARE-989011, 2000) [C].
- Allogeneic stem cell transplantation is also used increasingly, but it is still possible only for few patients (Bataille & Harousseau, 1997).

#### Related Evidence

- Early treatment of early stage multiple myeloma appears to inhibit disease progression and reduce vertebral compression. However, early treatment may increase the risk of acute leukaemia (He et al., 2003) [B].

#### Definitions:

#### Levels of Evidence

- Strong research-based evidence. Multiple relevant, high-quality scientific studies with homogeneous results.
- Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.
- Limited research-based evidence. At least one adequate scientific study.
- No research-based evidence. Expert panel evaluation of other information.

#### CLINICAL ALGORITHM(S)

None provided

### EVIDENCE SUPPORTING THE RECOMMENDATIONS

#### REFERENCES SUPPORTING THE RECOMMENDATIONS

[References open in a new window](#)

#### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the "Major Recommendations" field).



## BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

### POTENTIAL BENEFITS

Reduction of symptoms and prevention of complications through early diagnosis and treatment

### POTENTIAL HARMS

Not stated

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Living with Illness

### IOM DOMAIN

Effectiveness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Multiple myeloma (MM). In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2005 May 1 [Various].

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2001 Dec 27 (revised 2005 May 1)

### GUIDELINE DEVELOPER(S)

Finnish Medical Society Duodecim - Professional Association

## SOURCE(S) OF FUNDING

Finnish Medical Society Duodecim

## GUIDELINE COMMITTEE

Editorial Team of EBM Guidelines

## COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Author: Juhani Vilpo

## FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

## GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Vilpo J. Multiple myeloma (MM). In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2004 Jun 14 [various].

## GUIDELINE AVAILABILITY

This guideline is included in a CD-ROM titled "EBM Guidelines. Evidence-Based Medicine" available from Duodecim Medical Publications, Ltd, PO Box 713, 00101 Helsinki, Finland; e-mail: [info@ebm-guidelines.com](mailto:info@ebm-guidelines.com); Web site: [www.ebm-guidelines.com](http://www.ebm-guidelines.com).

## AVAILABILITY OF COMPANION DOCUMENTS

None available

## PATIENT RESOURCES

None available

## NGC STATUS

This summary was completed by ECRI on December 17, 2002. The information was verified by the guideline developer as of February 7, 2003. This NGC summary was updated by ECRI on October 5, 2004, and on June 24, 2005.

## COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 10/9/2006

